Gyroscope Therapeutics, spun out of Cambridge and Syncona, has merged with Orbit Biomedical to form a fully-integrated retinal gene therapy developer.
Gyroscope Therapeutics, a UK-based retinal gene therapy developer partly based on University of Cambridge research, has merged with US-based medical device manufacturer Orbit Biomedical.
The merged business will operate under the Gyroscope name and act as a fully-integrated gene therapy company with clinical, manufacturing and delivery capabilities. Gyroscope claimed in its announcement the merger would make it the first such end-to-end gene therapy provider.
Founded in 2016, Gyroscope is working on retinal gene therapies for dry age-related macular…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
